Haptogen’s unique approach is set to create valuable new therapeutic compounds.
Small is
beautiful…
30th
September 2002
:
Aberdeen
,
Scotland.
New company, Haptogen Ltd, has overcome the significant technical
difficulties associated with raising antibodies to the smallest of
small molecules - bioactive haptens. Now, for the first time, anti-hapten
therapeutics can be realised.
Haptogen
Ltd, formed earlier this year, is a spin-out from
Aberdeen
University
.
The founders have world-class scientific expertise in the area of
antibody engineering and its application to haptens. This know-how,
combined with the team’s proven commercial experience has created a
powerful company that is set to open up new opportunities in a wide
variety of therapeutic areas. Importantly, the company has a strong IP
position with core patents filed and relevant licences in hand.
Antibody
engineering has become one of the hottest topics and most productive
routes in drug discovery over recent years and it is now widely
accepted that this approach can reduce development times and increase
potential success, compared to classical drug development. In excess
of 200 antibody-based drugs are currently in pre-clinical development
and around 70 are in the clinic. Ten therapeutic antibody products
have already reached the market. Commercial isolation and production
of therapeutic antibody products has been concentrated on larger,
protein targets but now the Haptogen team has generated compelling
‘proof of principle’ data and a series of large antibody libraries
have been cloned and human anti-hapten antibodies to a range of
targets isolated and produced.
Haptogen’s
unique hapten-based antibody products will be brought to market either
on the company’s own account or with selected partners. Initial
development programmes are focussed toward the very large global
markets for anti-infective and anti-obesity drugs.
www.haptogen.com
Text
ends, contact details and picture follow…/
Press
contact: Richard Kent, Kapler Communications Ltd
Tel:
+44 (0)1480 471117
E-mail:
richard@kapleronline.com
Haptogen
contact: Dr Andy Porter
T:
+44 (0)1224 555870 (Direct line)
Email:
info@haptogen.com
A
colour photo of the Haptogen management team is available as a high
resolution digital file for publication - call or email Richard Kent
quoting reference HAP/PRL/001pic
Claire McLeod
Kapler Communications Ltd
+44 (0) 1480 471117
pr@kapleronline.com
